{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:26:07Z","timestamp":1747221967359,"version":"3.40.5"},"reference-count":38,"publisher":"Sociedade Brasileira de Cardiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,25]]},"DOI":"10.36660\/abc.20190218","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T20:08:19Z","timestamp":1586808499000},"source":"Crossref","is-referenced-by-count":2,"title":["Caracter\u00edsticas Cl\u00ednicas da Hipertens\u00e3o Arterial Resistente vs. Refrat\u00e1ria em uma Popula\u00e7\u00e3o de Hipertensos Afrodescendentes"],"prefix":"10.36660","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3745-0753","authenticated-orcid":false,"given":"Cristiano","family":"Macedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Junior","given":"Roque","family":"Aras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella Sales de","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","reference":[{"issue":"9","key":"key20200413160745_B1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","unstructured":"1. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046\u201358.","journal-title":"Circulation"},{"issue":"6","key":"key20200413160745_B2","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Pr","volume":"71","author":"Whelton","year":"2018","unstructured":"2. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Pr. Hypertension. 2018 Jun;71(6):e13\u2013115.","journal-title":"Hypertension"},{"issue":"3","key":"key20200413160745_B3","first-page":"1","article-title":"VII Diretriz Brasileira De Hipertens\u00e3o Arterial","volume":"107","author":"Malachias","year":"2016","unstructured":"3. Malachias M, Souza W, Plavnik F, Rodrigues C, Brand\u00e3o A, Neves M. VII Diretriz Brasileira De Hipertens\u00e3o Arterial. Arq Bras Cardiol. 2016;107(3 Supl.3):1\u201383.","journal-title":"Arq Bras Cardiol"},{"issue":"28","key":"key20200413160745_B4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","unstructured":"4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B\u00f6hm M, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159\u2013219.","journal-title":"Eur Heart J"},{"issue":"1","key":"key20200413160745_B5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1590\/S0066-782X2012000700002","article-title":"I Posicionamento Brasileiro Sobre Hipertens\u00e3o Arterial Resistente","volume":"99","author":"Departamento de Hipertens\u00e3o Arterial da Sociedade Brasileira de Cardiologia","year":"2012","unstructured":"5. Departamento de Hipertens\u00e3o Arterial da Sociedade Brasileira de Cardiologia. I Posicionamento Brasileiro Sobre Hipertens\u00e3o Arterial Resistente. Arq Bras Cardiol. 2012;99(1):576\u201385.","journal-title":"Arq Bras Cardiol"},{"issue":"2","key":"key20200413160745_B6","first-page":"129","article-title":"Refractory versus resistant hypertension: Novel distinctive phenotypes","volume":"21","author":"Dudenbostel","year":"2017","unstructured":"6. Tanja Dudenbostel*, Mohammed Siddiqui, Nitin Gharpure ADAC. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci. 2017;21(2):129\u201339.","journal-title":"J Nat Sci"},{"issue":"3","key":"key20200413160745_B7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.113.02026","article-title":"Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort","volume":"63","author":"Calhoun","year":"2014","unstructured":"7. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort. Hypertension. 2014;63(3):451\u20138.","journal-title":"Hypertension"},{"issue":"1","key":"key20200413160745_B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1751-7176.2011.00556.x","article-title":"Refractory hypertension: Definition, prevalence, and patient characteristics","volume":"14","author":"Acelajado","year":"2012","unstructured":"8. Acelajado MC, Pisoni R, Dudenbostel T, Dell\u2019Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: Definition, prevalence, and patient characteristics. J Clin Hypertens. 2012;14(1):7\u201312.","journal-title":"J Clin Hypertens"},{"issue":"25","key":"key20200413160745_B9","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","unstructured":"9. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510\u201326.","journal-title":"Circulation"},{"issue":"11","key":"key20200413160745_B10","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jch.12886","article-title":"Untreated, Uncontrolled, and Apparent Resistant Hypertension: Results of the German Health Examination Survey 2008-2011","volume":"18","author":"Sarganas","year":"2016","unstructured":"10. Sarganas G, Neuhauser HK. Untreated, Uncontrolled, and Apparent Resistant Hypertension: Results of the German Health Examination Survey 2008-2011. J Clin Hypertens. 2016;18(11):1146\u201354.","journal-title":"J Clin Hypertens"},{"issue":"8","key":"key20200413160745_B11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: Definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","unstructured":"11. Judd E, Calhoun DA. Apparent and true resistant hypertension: Definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463\u20138.","journal-title":"J Hum Hypertens"},{"issue":"40","key":"key20200413160745_B12","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/eurheartj\/ehv392","article-title":"Resistant hypertension: What the cardiologist needs to know","volume":"36","author":"Rimoldi","year":"2015","unstructured":"12. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: What the cardiologist needs to know. Eur Heart J. 2015;36(40):2686\u2013695c.","journal-title":"Eur Heart J"},{"issue":"1","key":"key20200413160745_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jhh.2013.46","article-title":"Resistant hypertension - Complex mix of secondary causes and comorbidities","volume":"28","author":"Dudenbostel","year":"2014","unstructured":"13. Dudenbostel T. Resistant hypertension - Complex mix of secondary causes and comorbidities. J Hum Hypertens. 2014;28(1):1\u20132.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"key20200413160745_B14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.115.05449","article-title":"Refractory hypertension: Evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure","volume":"66","author":"Dudenbostel","year":"2015","unstructured":"14. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: Evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126\u201333.","journal-title":"Hypertension"},{"issue":"1","key":"key20200413160745_B15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MNH.0000000000000286","article-title":"Refractory versus resistant hypertension","volume":"26","author":"Siddiqui","year":"2017","unstructured":"15. Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017;26(1):14\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"key20200413160745_B16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jash.2015.03.005","article-title":"Refractory and resistant hypertension: Characteristics and differences observed in a specialized clinic","volume":"9","author":"Modolo","year":"2015","unstructured":"16. Modolo R, De Faria AP, Sabbatini AR, Barbaro NR, Ritter AMV, Moreno H. Refractory and resistant hypertension: Characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9(5):397\u2013402.","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"key20200413160745_B17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","article-title":"Management of high blood pressure in blacks: An update of the International Society on Hypertension in Blacks consensus statement","volume":"56","author":"Flack","year":"2010","unstructured":"17. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, et al. Management of high blood pressure in blacks: An update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780\u2013800.","journal-title":"Hypertension"},{"issue":"1","key":"key20200413160745_B18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jch.12433","article-title":"Resistant hypertension: Risk factors, subclinical atherosclerosis, and comorbidities among adults-the brazilian longitudinal study of adult health (ELSA-Brasil)","volume":"17","author":"Lotufo","year":"2015","unstructured":"18. Lotufo PA, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant hypertension: Risk factors, subclinical atherosclerosis, and comorbidities among adults-the brazilian longitudinal study of adult health (ELSA-Brasil). J Clin Hypertens. 2015;17(1):74\u201380.","journal-title":"J Clin Hypertens"},{"issue":"5","key":"key20200413160745_B19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12170-013-0326-9","article-title":"Resistant Hypertension","volume":"7","author":"Boolani","year":"2013","unstructured":"19. Boolani H, Sinha A, Randall O. Resistant Hypertension. Curr Cardiovasc Risk Rep. 2013;7(5):354\u201363.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"7","key":"key20200413160745_B20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1311989","article-title":"Association of Urinary Sodium and Potassium Excretion with Blood Pressure","volume":"371","author":"Mente","year":"2014","unstructured":"20. Mente A, O\u2019Donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A, et al. Association of Urinary Sodium and Potassium Excretion with Blood Pressure. N Engl J Med. 2014;371(7):601\u201311.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20200413160745_B21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MBP.0b013e3282feebd5","article-title":"Omron HEM-711 DLX home Blood pressure monitor passes the European Society of Hypertension International Validation Protocol","volume":"13","author":"Grim","year":"2008","unstructured":"21. Grim CE, Grim CM. Omron HEM-711 DLX home Blood pressure monitor passes the European Society of Hypertension International Validation Protocol. Blood Press Monit. 2008 Aug;13(4):225\u20136.","journal-title":"Blood Press Monit"},{"issue":"5","key":"key20200413160745_B22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1590\/S0066-782X2011005000038","article-title":"Precis\u00e3o do Aparelho Omron HEM-705 CP na Medida de Press\u00e3o Arterial em Grandes Estudos Epidemiol\u00f3gicos","volume":"96","author":"Vera-Cala","year":"2011","unstructured":"22. Vera-Cala LM, Orostegui M, Valencia-Angel LI, L\u00f3pez N, Bautista LE. Precis\u00e3o do Aparelho Omron HEM-705 CP na Medida de Press\u00e3o Arterial em Grandes Estudos Epidemiol\u00f3gicos. Arq Bras Cardiol. 2011;96(5):393\u20138.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"key20200413160745_B23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","unstructured":"23. Cockcroft DW & Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"3","key":"key20200413160745_B24","first-page":"185","article-title":"Estimativa da Fun\u00e7\u00e3o Renal pela F\u00f3rmula de Cockcroft e Gault em Pacientes com Sobrepeso ou com Obesidade Estimation of Renal Function by the Cockcroft and Gault Formula in Overweighted or Obese Patients","volume":"30","author":"Napoli","year":"2008","unstructured":"24. Napoli Filho M Di, Burmeister JE, Miltersteiner R, Machado B, Generali M. Estimativa da Fun\u00e7\u00e3o Renal pela F\u00f3rmula de Cockcroft e Gault em Pacientes com Sobrepeso ou com Obesidade Estimation of Renal Function by the Cockcroft and Gault Formula in Overweighted or Obese Patients. J Bras Nefrol. 2008;30(3):185\u201391.","journal-title":"J Bras Nefrol"},{"issue":"1","key":"key20200413160745_B25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1590\/S0066-782X2012005000053","article-title":"Rela\u00e7\u00e3o entre a Escala de Ades\u00e3o Terap\u00eautica de oito itens de Morisky (MMAS-8) e o controle da press\u00e3o arterial","volume":"99","author":"Oliveira-Filho","year":"2012","unstructured":"25. Oliveira-Filho AD, Barreto-Filho JA, Neves SJF, Lyra Junior DP de. Rela\u00e7\u00e3o entre a Escala de Ades\u00e3o Terap\u00eautica de oito itens de Morisky (MMAS-8) e o controle da press\u00e3o arterial. Arq Bras Cardiol. 2012;99(1):649\u201358.","journal-title":"Arq Bras Cardiol"},{"issue":"5","key":"key20200413160745_B26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive Validity of A Madication Adherence Measure in an Outpatient Setting","volume":"10","author":"Morisky","year":"2008","unstructured":"26. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive Validity of A Madication Adherence Measure in an Outpatient Setting. J Clin Hypertens. 2008;10(5):348\u201354.","journal-title":"J Clin Hypertens"},{"issue":"9","key":"key20200413160745_B27","first-page":"1","article-title":"Refractory versus resistant hypertension: Novel distinctive phenotypes","volume":"3","author":"Dudenbostel","year":"2017","unstructured":"27. Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci. 2017;3(9):1\u20136.","journal-title":"J Nat Sci"},{"issue":"6","key":"key20200413160745_B28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","unstructured":"28. Cushman WC, Ford CE, Cutler J a, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393\u2013404.","journal-title":"J Clin Hypertens"},{"issue":"13","key":"key20200413160745_B29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","unstructured":"29. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342.","journal-title":"Circulation"},{"issue":"5","key":"key20200413160745_B30","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"64","author":"Muntner","year":"2014","unstructured":"30. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014;64(5):1012\u201321.","journal-title":"Hypertension"},{"issue":"11","key":"key20200413160745_B31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jash.2016.08.008","article-title":"Prevalence of treatment-resistant hypertension and important associated factors\u2014results from the Swedish Primary Care Cardiovascular Database","volume":"10","author":"Holmqvist","year":"2016","unstructured":"31. Holmqvist L, Bostr\u00f6m KB, Kahan T, Schi\u00f6ler L, Hasselstr\u00f6m J, Hjerpe P, et al. Prevalence of treatment-resistant hypertension and important associated factors\u2014results from the Swedish Primary Care Cardiovascular Database. J Am Soc Hypertens. 2016;10(11):838\u201346.","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"key20200413160745_B32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"De La Sierra","year":"2011","unstructured":"32. De La Sierra A, Segura J, Banegas JR, Gorostidi M, De La Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898\u2013902.","journal-title":"Hypertension"},{"issue":"6","key":"key20200413160745_B33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","unstructured":"33. V\u00e1clav\u00edk J, Sedl\u00e1k R, Plach\u00fd M, Navr\u00e1til K, Pl\u00e1\u0161ek J, Jarkovsk\u00fd J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069\u201375.","journal-title":"Hypertension"},{"issue":"10008","key":"key20200413160745_B34","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","unstructured":"34. Williams B, Macdonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368.","journal-title":"Lancet"},{"issue":"3","key":"key20200413160745_B35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s11906-013-0349-0","article-title":"Role of ambulatory blood pressure monitoring in resistant hypertension","volume":"15","author":"Grassi","year":"2013","unstructured":"35. Grassi G, Bombelli M, Seravalle G, Brambilla G, Dell\u2019Oro R, Mancia G. Role of ambulatory blood pressure monitoring in resistant hypertension. Curr Hypertens Rep. 2013;15(3):232\u20137.","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"key20200413160745_B36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jash.2014.03.003","article-title":"Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality","volume":"8","author":"Irvin","year":"2014","unstructured":"36. Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8(6):405\u201313.","journal-title":"J Am Soc Hypertens"},{"issue":"9","key":"key20200413160745_B37","article-title":"Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care","volume":"7","author":"Beus","year":"2017","unstructured":"37. de Beus E, van der Sande NGC, Bots ML, Spiering W, Voskuil M, Visseren FLJ, et al. Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care. BMJ Open. 2017;7(9):e016692.","journal-title":"BMJ Open"},{"issue":"6","key":"key20200413160745_B38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005477","article-title":"Racial Differences in Arterial Stiffness are Mainly Determined by Blood Pressure Levels: Results From the ELSA \u2013 Brasil Study","volume":"6","author":"Baldo","year":"2017","unstructured":"38. Baldo MP, Cunha RS, Ribeiro ALP, Lotufo PA, Chor D, Barreto SM, et al. Racial Differences in Arterial Stiffness are Mainly Determined by Blood Pressure Levels: Results From the ELSA \u2013 Brasil Study. J Am Heart Assoc. 2017;6(6):e005477.","journal-title":"J Am Heart Assoc"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.scielo.br\/pdf\/abc\/v115n1\/0066-782X-abc-115-01-0031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:43:54Z","timestamp":1614962634000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0066-782X2020005005203&lng=pt&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":38,"alternative-id":["10.36660\/abc.20190218"],"URL":"https:\/\/doi.org\/10.36660\/abc.20190218","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"type":"print","value":"0066-782X"},{"type":"electronic","value":"1678-4170"}],"subject":[],"published":{"date-parts":[[2020,3,25]]}}}